Table 4.

Adjusted relative risk of TGCTs by quartile of PCB groupings in the STEED study

ControlsAll TGCTSeminomaNonseminoma
nnOR * (95% CI)nOR * (95% CI)nOR * (95% CI)
Wolff group 1B (101, 187)
(potentially estrogenic, weak phenobarbital inducers)
    Q12272141.00641.001501.00
    Q22291930.88 (0.66–1.18)770.97 (0.64–1.48)1160.83 (0.59–1.16)
    Q32281560.64 (0.46–0.89)760.77 (0.49–1.22)790.56 (0.38–0.83)
    Q42281710.65 (0.46–0.93)950.80 (0.49–1.29)760.55 (0.36–0.84)
    Ptrend0.020.330.004
Wolff group 2A (118, 156)
(potentially antiestrogenic, immunotoxic, dioxin-like, non-ortho and mono-ortho substituted)
    Q12292441.00751.001691.00
    Q22271560.59 (0.44–0.79)610.64 (0.42–0.99)950.56 (0.40–0.79)
    Q32281890.62 (0.45–0.85)1020.83 (0.54–1.28)870.50 (0.34–0.72)
    Q42291470.42 (0.29–0.59)750.44 (0.27–0.72)710.38 (0.25–0.58)
    Ptrend<0.00010.002<0.0001
Wolff group 2B (138, 170)
(potentially antiestrogenic, immunotoxic, limited dioxin activity, di-ortho substituted)
    Q12282311.00711.001601.00
    Q22281640.66 (0.49–0.90)600.70 (0.45–1.08)1040.68 (0.48–0.95)
    Q32281760.58 (0.42–0.81)920.75 (0.48–1.17)840.49 (0.33–0.73)
    Q42291650.46 (0.31–0.67)900.49 (0.29–0.83)740.43 (0.27–0.68)
    Ptrend0.00020.010.0004
Wolff group 3 (99, 153, 180, 183)
(phenobarbital, CYP1A, and CYP2B inducers)
    Q12282331.00751.001581.00
    Q22281610.63 (0.47–0.85)600.63 (0.41–0.97)1010.64 (0.46–0.91)
    Q32281710.57 (0.41–0.80)860.64 (0.40–1.00)840.53 (0.36–0.78)
    Q42281700.49 (0.34–0.70)8920.49 (0.29–0.81)780.46 (0.29–0.71)
    Ptrend0.0020.020.003
UDP-GT, CYP1A, and CYP2B inducers (99, 101, 118, 153, 156, 180, 183, 187)
    Q12282361.00751.001611.00
    Q22281660.64 (0.48–0.87)620.67 (0.44–1.02)1040.65 (0.46–0.91)
    Q32281660.55 (0.39–0.76)850.64 (0.41–1.00)800.47 (0.32–0.70)
    Q42281660.47 (0.33–0.68)900.50 (0.30–0.83)760.44 (0.28–0.68)
    Ptrend0.00050.0030.03
Phenobarbitol inducers (99, 101, 153, 163, 180, 183)
    Q12282341.00741.001601.00
    Q22281660.65 (0.48–0.87)680.74 (0.49–1.12)980.61 (0.43–0.86)
    Q32281720.58 (0.42–0.81)820.62 (0.39–0.97)890.55 (0.38–0.81)
    Q42281620.46 (0.32–0.66)880.47 (0.29–0.79)740.43 (0.28–0.67)
    Ptrend0.00030.0060.0009
Mixed function oxidase inducers (118, 138, 156, 170)
    Q12222331.00731.001601.00
    Q22341730.63 (0.46–0.84)660.64 (0.42–0.99)1070.65 (0.46–0.91)
    Q32281750.54 (0.39–0.75)900.66 (0.42–1.03)850.47 (0.32–0.69)
    Q42291550.41 (0.38–0.60)840.42 (0.25–0.71)700.39 (0.25–0.61)
    Ptrend<0.00010.003<0.0001
Total PCBs (99, 101, 118, 138, 153, 156, 163, 170, 180, 183, 187)
    Q12282351.00751.001601.00
    Q22281630.62 (0.46–0.83)580.58 (0.38–0.90)1050.65 (0.46–0.92)
    Q32281690.55 (0.40–0.77)920.67 (0.42–1.05)770.46 (0.31–0.69)
    Q42281670.46 (0.32–0.67)870.45 (0.27–0.76)790.45 (0.29–0.71)
    Ptrend0.00040.010.001
Total PCB exposure
    Q12282241.00741.001501.00
    Q22271710.88 (0.67–1.16)600.90 (0.60–1.35)1110.84 (0.61–1.15)
    Q32271750.73 (0.54–0.98)910.89 (0.59–1.34)840.62 (0.43–0.88)
    Q42281620.61 (0.43–0.86)880.64 (0.41–1.02)730.55 (0.37–0.83)
    Ptrend0.0060.050.007
  • * Adjusted for matching variables, serum DDE level, age at serum draw, BMI, and height.

  • Total PCB exposure is sum of all PCB observations above the limit of detection for all PCBs assayed: 28, 52, 99, 101, 118, 128, 138, 153, 156, 163, 170, 180, 183, and 187.